GlassScriptPhysician profile
James E Naifeh
NPI 1528006673
$3,025.81
in general payments reported to CMS, 2019-2025
22 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $727 · 2021: $355 · 2022: $328 · 2023: $432 · 2024: $442 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,173.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $521.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $480.20 | 2021-2025 | |
| Lilly USA, LLC | $269.45 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $264.13 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.62 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $163.61 | 2019-2021 | |
| Pfizer INC. | $162.15 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.43 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $148.30 | 2019-2020 | |
| Abbott Laboratories | $100.32 | 2022-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $99.35 | 2023-2024 | Quviviq |
| Amgen INC. | $90.72 | 2020-2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $68.29 | 2023-2024 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $47.86 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.95 | 2024 | Xifaxan, Trulance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41.09 | 2020 | |
| Dexcom, INC. | $34.01 | 2022-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $29.48 | 2024-2025 | Vyepti |
| Novo Nordisk INC | $22.61 | 2020 | |
| Verona Pharma, INC. | $19.11 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $16.60 | 2024 | Voquezna |
| Supernus Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Naifeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.